Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Comment by TheeRookon Aug 06, 2020 9:05pm
168 Views
Post# 31376607

RE:RE:RE:RE:RE:RE:Field tests

RE:RE:RE:RE:RE:RE:Field testsThis is a tough one especially the Flex  Studies has to be done to failure..  Nothing like this was ever published by SONA from the MRI results.   So is manual easier or harder.??


J. PERFORMANCE EVALUATION
We recommend including the studies listed below (as applicable) in your EUA request.  Please note that, particularly for new technologies, FDA may request additional studies so we can adequately assess the risks and benefits associated with the device:
 
1) Limit of Detection (LoD) - Analytical Sensitivity 
Please provide information consistent with the recommendations in the Antigen Template for Manufacturers or Molecular Diagnostic Template for Manufacturers.
 
2) Inclusivity (analytical sensitivity) 
Please provide information consistent with the recommendations in the Antigen Template for Manufacturers or Molecular Diagnostic Template for Manufacturers.
 
3) Cross-reactivity (Analytical Specificity) 
Please provide information consistent with the recommendations in the Antigen Template for Manufacturers or Molecular Diagnostic Template for Manufacturers. For all tests intended for use in a non-laboratory setting (e.g., a complete home test), FDA recommends wet testing of Cross-reactivity and Microbial Interference in addition to in silico analysis.
a. Cross-reactivity (organisms tested in the absence of SARS-CoV-2)
b. Microbial Interference Studies (organisms tested in the presence of SARS-CoV-2) 
c. Endogenous Interference Substances Studies (including common household items such as cleaners, lotions, soap etc.) 
 
4) High-dose Hook Effect Study for antigen tests
Please provide information consistent with the recommendations in the Antigen Template for Manufacturers.
 
5) Biotin interference, if applicable  
Please provide information consistent with the recommendations in the Antigen Template for Manufacturers.
 
6) Flex Studies
Flex studies assess the robustness of an assay performed with the device in its final design/format and should be performed in-house by staff who have been trained in the use of the test.  The flex studies should evaluate the most common or likely sources of error based on the use locations and test procedure.  Flex studies should be conducted by testing a negative sample and a low positive sample (at 1.5x - 2x LoD) for each condition being evaluated. In general, the flex studies should be conducted to the point of failure to determine the maximum deviation that will allow for generating accurate results.  We recommend 3 replicates per condition per sample concentration.  Data for each condition evaluated (i.e., line data) should be provided. If erroneous results are observed during studies evaluating the robustness of the device, adequate mitigation(s) should be provided.  Each study should be performed using a pre-defined study protocol that includes the following: 
i. The objective of the study
ii. Detailed test procedure
iii. Materials used
 
An example of some conditions that may be evaluated as potential user errors and anticipated environmental stresses (temperature and humidity extremes) are shown below:
iv. 40°C and 95% RH (mimicking hot and humid climates)
v. Delay in sample testing
vi. Delay in operational steps
vii. Delay in reading results
viii. Sample volume variability (if applicable)
ix. Buffer volume variability (if applicable)
x. Mixing/swab expression variability (if applicable)
xi. Disturbance during analysis
xii. Placement on non-level surface
xiii. Impact of different light sources (if applicable)
xiv. If hand-held, positioning at 90° angle (simulating placing device in pocket or lifting to see result display screen)
 
 
<< Previous
Bullboard Posts
Next >>